The upside case is a transition from pilot hardware to recurring per-scan + reading + software revenue. The risk case is slow adoption and continued dilution before unit economics are proven.

If Nanox converts ARC/ARC X from pilots into repeatable go-lives with reliable uptime and reimbursement-supported utilization, it can shift from “selling boxes” to recurring per-scan + reading + software revenue, earning a platform-like re-rate despite ongoing regulatory and financing gates.

Aligned via automation of diagnostic cognition and a workflow/network thesis (devices + cloud + radiologist network), but heavily gated by permissioning, trust, and proof of unit economics.

Nanox is effectively a call option on turning radiology into a recurring “utility” model: more installed systems matter only if they convert to paid scan flow, attach services (reads/workflow), and prove reliability. If it demonstrates repeatable implementations at a U.S. chain plus first credible EU installs, investor trust can improve and the company can be valued closer to scaled medtech/services peers rather than pre-commercial hardware. The ceiling is capped by regulatory/reimbursement cadence and dilution risk, so the base case remains “prove it, then scale.”

The binding risks are external gates (permissioning and reimbursement-driven adoption) plus internal commercialization physics (repeatable go-lives, uptime, utilization, and margin). If those don’t tighten before the next capital need, dilution and credibility loss can dominate equity outcomes.

Higher confidence in a viable ramp path after 2026 revenue guidance and post-November financing improved runway, but still gated by proof of repeatable utilization.

$8.15